Clinical Research Directory

Inclusion Criteria: * Age between18 to 75 years * Presence of hepatic steatosis, suggested by a controlled attenuation parameter (CAP) ≥ 252 dB/m on elastometry and elevated transaminases (ALT ≥ 25 or 33 IU/L in women or men respectively) * Presence of overweight (BMI \> 25 kg/m²), obesity (BMI \> 30 kg/m²), metabolic syndrome, prediabetes or type 2 diabetes. Metabolic syndrome is defined by int ernational Diabetes Federation as follows : waist circumference ≥ 94/80cm for men/women with ≥ 2 other criteria: arterial pressure ≥ 130/85 mmHg or treatment for hypertension, fasting glucose ≥ 130/85 mmHg or treatment for hypertension, serum triglycerides \> 150 mg/dl or treatment for dyslipidemia, HDL cholesterol \< 40/50 mg/dl for men/women or treatment for dyslipidemia. Exclusion Criteria: * Liver disease from other causes (alcohol, active viral chronic hepatitis B or C, Wilson\'s disease, autoimmune hepatitis, alpha1-anti-trypsin deficiency,...) * Heavy consumption of alcoholic beverages, i.e. \> 140 g or 210 g of ethanol in women or men respectively). * Intravenous drug use * HbA1C \> 10% * Decompensated cirrhosis (presence of ascites, bilirubin level \> 1.2 mg/dL in a patient without Gilbert's syndrome, albumin level \< 35 g/L) * Pregnancy * Use of drugs that may cause steatosis (methotrexate, amiodarone, tamoxifen, oral corticosteroids) currently or in the last 3 months * Change in treatment of hyperglycaemia (dose or medication) in the last 3 months * Change in body weight \>5% in the last 3 months * Active cancer * End stage renal disease or dialysis * Type 1 diabetes or secondary diabetes * Digestive malabsorption * Untreated thyroid disease * Taking a treatment under study or approved for NASH (semaglutide, lanifibranor, obeticholic acid). * Musculoskeletal disorders, neuromuscular or inflammatory diseases such as connective tissue diseases, myositis and vasculitis that have musculoskeletal manifestations.